DE602004007364D1 - Verwendung von pyridin-2-yl-methylaminderivaten zur behandlung von chronischen schmerz-symptomen neuropathischen oder psychogenen ursprungs. - Google Patents
Verwendung von pyridin-2-yl-methylaminderivaten zur behandlung von chronischen schmerz-symptomen neuropathischen oder psychogenen ursprungs.Info
- Publication number
- DE602004007364D1 DE602004007364D1 DE602004007364T DE602004007364T DE602004007364D1 DE 602004007364 D1 DE602004007364 D1 DE 602004007364D1 DE 602004007364 T DE602004007364 T DE 602004007364T DE 602004007364 T DE602004007364 T DE 602004007364T DE 602004007364 D1 DE602004007364 D1 DE 602004007364D1
- Authority
- DE
- Germany
- Prior art keywords
- neuropathic
- treatment
- analgesic
- chronic pain
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000002193 Pain Diseases 0.000 title abstract 4
- 208000000094 Chronic Pain Diseases 0.000 title abstract 3
- 230000002981 neuropathic effect Effects 0.000 title abstract 3
- 230000001107 psychogenic effect Effects 0.000 title abstract 3
- SVEUVITYHIHZQE-UHFFFAOYSA-N n-methylpyridin-2-amine Chemical class CNC1=CC=CC=N1 SVEUVITYHIHZQE-UHFFFAOYSA-N 0.000 title 1
- 230000000202 analgesic effect Effects 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- QBELHBBOLZORGR-UHFFFAOYSA-N (3-chloro-4-fluorophenyl)-[4-fluoro-2-[[(5-methylpyridin-2-yl)methylamino]methyl]piperidin-1-yl]methanone Chemical compound N1=CC(C)=CC=C1CNCC1N(C(=O)C=2C=C(Cl)C(F)=CC=2)CCC(F)C1 QBELHBBOLZORGR-UHFFFAOYSA-N 0.000 abstract 2
- 230000036592 analgesia Effects 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 abstract 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 1
- 241000700159 Rattus Species 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 abstract 1
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- SWKAGCAGUZJGSS-UHFFFAOYSA-N phenyl-[4-[(pyridin-2-ylmethylamino)methyl]piperidin-1-yl]methanone Chemical class C=1C=CC=CC=1C(=O)N(CC1)CCC1CNCC1=CC=CC=N1 SWKAGCAGUZJGSS-UHFFFAOYSA-N 0.000 abstract 1
- 150000003222 pyridines Chemical class 0.000 abstract 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0303099 | 2003-03-13 | ||
| FR0303099A FR2852244B1 (fr) | 2003-03-13 | 2003-03-13 | Utilisation de derives de pyridin-2-yl-methylamine pour la preparation d'un medicament destine au traitement des symptomes de la douleur chronique d'origine neuropathique ou psychogene |
| PCT/FR2004/000630 WO2004083171A2 (fr) | 2003-03-13 | 2004-03-15 | Utilisation de derives de pyridin-2-yl-methylamine pour le traitement des symptomes de la douleur chronique neuropathique ou psychogene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE602004007364D1 true DE602004007364D1 (de) | 2007-08-16 |
| DE602004007364T2 DE602004007364T2 (de) | 2008-03-06 |
Family
ID=32893267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004007364T Expired - Lifetime DE602004007364T2 (de) | 2003-03-13 | 2004-03-15 | Verwendung von pyridin-2-yl-methylaminderivaten zur behandlung von chronischen schmerz-symptomen neuropathischen oder psychogenen ursprungs. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8609694B2 (de) |
| EP (1) | EP1603564B1 (de) |
| JP (1) | JP4684994B2 (de) |
| KR (1) | KR101100002B1 (de) |
| CN (1) | CN1761467B (de) |
| AT (1) | ATE366111T1 (de) |
| AU (1) | AU2004222051B2 (de) |
| BR (1) | BRPI0408293A (de) |
| CA (1) | CA2518591C (de) |
| CY (1) | CY1106900T1 (de) |
| DE (1) | DE602004007364T2 (de) |
| DK (1) | DK1603564T3 (de) |
| ES (1) | ES2289494T3 (de) |
| FR (1) | FR2852244B1 (de) |
| HK (1) | HK1079120A1 (de) |
| IL (1) | IL170743A (de) |
| MX (1) | MXPA05009782A (de) |
| NO (1) | NO334997B1 (de) |
| NZ (1) | NZ542461A (de) |
| PL (1) | PL1603564T3 (de) |
| PT (1) | PT1603564E (de) |
| RU (1) | RU2359674C2 (de) |
| UA (1) | UA81023C2 (de) |
| WO (1) | WO2004083171A2 (de) |
| ZA (1) | ZA200507634B (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071778B2 (en) | 2006-07-27 | 2011-12-06 | Bristol-Myers Squibb Company | Substituted heterocyclic ethers and their use in CNS disorders |
| WO2009096941A1 (en) * | 2008-01-28 | 2009-08-06 | Bristol-Myers Squibb Company | Substituted heterocyclic ethers and their use in cns disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3925662B2 (ja) | 1995-01-12 | 2007-06-06 | グラクソ，グループ，リミテッド | タキキニンアンタゴニスト活性を有するピペリジン誘導体 |
| FR2755967B1 (fr) * | 1996-11-21 | 1999-01-29 | Pf Medicament | Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments |
| FR2784378B1 (fr) * | 1998-10-09 | 2000-12-29 | Pf Medicament | Nouveaux derives d'aryl-(4-fluoro-4-[(2-pyridin-2-yl- ethylamino)-methyl]-piperidin-1-yl)-methanone, leur procede de preparation et leur utilisation a titre de medicaments |
| FR2840900B1 (fr) * | 2002-06-18 | 2005-02-25 | Pf Medicament | Nouveaux derives d'aryl[4-halogeno-4- [(heteroaryl-methylamino)-methyl]-piperidin-1-yl]-methanone, leur procede de preparation et leur utilisation a titre de medicaments |
-
2003
- 2003-03-13 FR FR0303099A patent/FR2852244B1/fr not_active Expired - Fee Related
-
2004
- 2004-03-15 CA CA2518591A patent/CA2518591C/fr not_active Expired - Lifetime
- 2004-03-15 PL PL04720637T patent/PL1603564T3/pl unknown
- 2004-03-15 KR KR1020057017151A patent/KR101100002B1/ko active IP Right Grant
- 2004-03-15 DK DK04720637T patent/DK1603564T3/da active
- 2004-03-15 AU AU2004222051A patent/AU2004222051B2/en not_active Ceased
- 2004-03-15 DE DE602004007364T patent/DE602004007364T2/de not_active Expired - Lifetime
- 2004-03-15 WO PCT/FR2004/000630 patent/WO2004083171A2/fr active IP Right Grant
- 2004-03-15 EP EP04720637A patent/EP1603564B1/de not_active Expired - Lifetime
- 2004-03-15 BR BRPI0408293-1A patent/BRPI0408293A/pt not_active Application Discontinuation
- 2004-03-15 MX MXPA05009782A patent/MXPA05009782A/es active IP Right Grant
- 2004-03-15 US US10/549,076 patent/US8609694B2/en active Active
- 2004-03-15 PT PT04720637T patent/PT1603564E/pt unknown
- 2004-03-15 AT AT04720637T patent/ATE366111T1/de active
- 2004-03-15 RU RU2005131615/15A patent/RU2359674C2/ru not_active IP Right Cessation
- 2004-03-15 ES ES04720637T patent/ES2289494T3/es not_active Expired - Lifetime
- 2004-03-15 JP JP2006505728A patent/JP4684994B2/ja not_active Expired - Lifetime
- 2004-03-15 NZ NZ542461A patent/NZ542461A/en not_active IP Right Cessation
- 2004-03-15 UA UAA200509594A patent/UA81023C2/uk unknown
- 2004-03-15 CN CN2004800068827A patent/CN1761467B/zh not_active Expired - Lifetime
-
2005
- 2005-09-08 IL IL170743A patent/IL170743A/en not_active IP Right Cessation
- 2005-09-21 ZA ZA200507634A patent/ZA200507634B/en unknown
- 2005-10-11 NO NO20054673A patent/NO334997B1/no not_active IP Right Cessation
-
2006
- 2006-01-24 HK HK06101061A patent/HK1079120A1/xx not_active IP Right Cessation
-
2007
- 2007-10-02 CY CY20071101255T patent/CY1106900T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Westerink et al. | Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum | |
| Dobrydnjov et al. | Postoperative pain relief following intrathecal bupivacaine combined with intrathecal or oral clonidine | |
| DE69728585T2 (de) | Mittel gegen Juckreiz | |
| KR101855357B1 (ko) | 오피오이드 유도성 통각과민에서의 시그마 리간드의 용도 | |
| AU2007221135A1 (en) | Methods for regulating neurotransmitter systems by inducing counteradaptations | |
| PL1691892T3 (pl) | Odporna na fizyczne manipulowanie, współwytłaczana postać dawkowania zawierająca środek aktywny i środek przeciwdziałający oraz sposób wytwarzania tej postaci | |
| ATE396999T1 (de) | Morphinanderivate substituiert in position 14 und deren quartäre ammoniumsalze, herstellungsverfahren und verwendung | |
| NO20050417L (no) | Azaindol kinase-inhibitorer | |
| PE20060176A1 (es) | Antagonistas de cgrp seleccionados, procedimientos para su preparacion, y su empleo como medicamentos | |
| MA28706B1 (fr) | Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques | |
| ES2955490T3 (es) | Métodos y composiciones para potenciar la acción de los analgésicos opioides mediante el uso de alcaloides de la iboga | |
| US20120208751A1 (en) | Methods for Regulating Neurotransmitter Systems by Inducing Counteradaptations | |
| KR20110021823A (ko) | 진통 내성 억제제 | |
| MXPA03007885A (es) | Norbuprenorfina n-but-3-enilo y metodos de uso. | |
| ATE403426T1 (de) | Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen | |
| Horita et al. | Effects of TRH on the central nervous system of the rabbit | |
| CY1106900T1 (el) | Χρηση παραγωγων πυριδιν-2-υλμεθυλαμινης για τη θεραπεια συμπτωματων χρονιου πονου νευροπαθους ή ψυχογενους προελευσης | |
| US20070105940A1 (en) | Method for treating pain | |
| US20070259945A1 (en) | Method for treating pain | |
| Lauretti | Highlights in opioid agonists and antagonists | |
| Kamali et al. | Analgesic efficacy of bupivacaine alone versus bupivacaine plus dexmedetomidine in penile block for hypospadias surgery | |
| Xuelun et al. | Analgesic effect of morphine added to bupivacaine in transversus abdominis plane block for total abdominal hysterectomy | |
| Ashton et al. | Neuropharmacological profile of R 18 503-induced wet-shake behavior in the rat: Noradrenergic and opiate components | |
| Hass et al. | Physiological effects of a novel bioactive agent | |
| WO2018030382A1 (ja) | モルヒナン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |